This bill amends the Federal Food, Drug, and Cosmetic Act to require the FDA to tell an abbreviated new drug application (ANDA) applicant — or a prospective applicant in controlled correspondence — whether a proposed generic product is qualitatively and quantitatively the same as the listed drug when the drugs share inactive ingredients or when an in vitro bioequivalence approach is justified. If the FDA finds a mismatch, it must identify which inactive ingredient(s) differ and disclose the amount of any quantitative deviation.
The bill also limits the agency’s ability to later rescind a ‘same’ determination except where the listed drug’s formulation was withdrawn for safety/effectiveness or where the agency finds a clear error; it requires the agency to publish draft and final guidance (with a minimum 60-day comment period) within specified deadlines and makes the new disclosure authority explicitly permissible under federal confidentiality law. Practically, the measure narrows a key uncertainty for generic manufacturers, shifts informational burdens inside FDA review, and raises trade-secret and resource questions for regulators and brand companies alike.
At a Glance
What It Does
The bill adds a new subsection directing FDA to inform ANDA filers — upon request or on its own initiative during review — whether a candidate generic is qualitatively and quantitatively the same as the listed drug and, if not, to identify the differing inactive ingredients and quantify deviations. It bars changing a 'same' finding after an ANDA is filed except for a changed listed-drug formulation withdrawn for safety/effectiveness or identified agency error.
Who It Affects
ANDA applicants and prospective applicants using the controlled-correspondence process, FDA reviewers and compliance staff, brand drug holders whose listed-drug formulations are evaluated, and contract laboratories or formulators who supply inactive-ingredient specifications.
Why It Matters
The measure converts previously opaque FDA judgments about inactive ingredients into discrete, actionable disclosures, reducing regulatory guesswork that can delay generic development. It also compels timely guidance from FDA, making the agency’s approach to assessing pH adjusters and other excipients public and subject to comment.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a narrowly tailored, requestable transparency mechanism inside the ANDA pathway. A company that has submitted or plans to submit an abbreviated application — or an interested party using controlled correspondence — can ask FDA whether a proposed generic contains the same inactive ingredients in the same concentrations as the listed drug, or whether the agency accepts an in vitro bioequivalence approach for a drug with matching excipients.
FDA may also volunteer this determination while it is reviewing an ANDA.
When FDA concludes the proposed product is not qualitatively or quantitatively the same, the agency must do more than say “no.” It must point to the specific inactive ingredient(s) responsible for the mismatch and provide numeric information about any quantitative deviations. That requirement turns subjective chemistry judgments into discrete technical facts that applicants can act on — reformulate, supply additional data, or challenge the agency’s view.If FDA says a product is qualitatively and quantitatively the same, the bill restricts the agency’s ability to reverse that decision after an ANDA is submitted.
FDA can only change course if the listed drug’s formulation was itself altered and withdrawn for safety/effectiveness reasons, or if FDA later identifies an error and memorializes that error in writing and provides the applicant with notice. Those protections give applicants a measure of finality that can preserve investments in formulation and testing.The statute also requires FDA to publish draft guidance within one year describing how it will make these determinations — including its approach to assessing pH adjusters — allow at least 60 days of public comment, and finalize the guidance within a year after the comment period closes.
Importantly, the new disclosure authority is explicitly stated to be lawful under confidentiality rules (18 U.S.C. 1905), addressing one common procedural obstacle to sharing proprietary information between the agency and applicants. The bill applies immediately on enactment, even if the guidance is not yet final.
The Five Things You Need to Know
The bill adds a new 505(j)(3)(H) requiring FDA to state whether a proposed generic is qualitatively and quantitatively the same as the listed drug when inactive ingredients match or an in vitro approach is justified.
If FDA finds a mismatch, it must identify the specific inactive ingredient(s) responsible and disclose the amount of any quantitative deviation.
FDA may not change a ‘same’ determination after an ANDA is filed except if the listed drug’s formulation was changed and withdrawn for safety/effectiveness or if the agency issues a written error determination and provides notice.
The Secretary must publish draft guidance within one year on how FDA will make these determinations (including pH adjusters), allow at least 60 days for comment, and finalize guidance within a year after the comment period closes.
The bill clarifies that the disclosures are authorized by law despite confidentiality statutes (referencing 18 U.S.C. 1905), removing a legal barrier to sharing this information with applicants.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Requestable determinations and proactive disclosures
This provision creates the trigger: an ANDA filer (or a party using controlled correspondence) can ask FDA whether a proposed generic is qualitatively and quantitatively identical to the listed drug when inactive ingredients are required to match or when an in vitro bioequivalence strategy is appropriate. The clause also lets FDA proactively give the same determination during ANDA review. Practically, this formalizes an information flow that previously depended on informal interactions or opaque internal review notes.
Mandatory identification and quantification of deviations
When FDA determines a product is not qualitatively or quantitatively the same, the agency must name the specific inactive ingredient(s) at issue and disclose the size of any quantitative deviations. That creates a discrete remediation path for applicants (reformulation, additional data, or targeted dispute) and forces FDA to translate chemistry-based judgments into enumerated findings — a significant procedural shift for review memos and deficiency letters.
Limits on rescinding ‘same’ determinations and notice requirement
If FDA finds a product is the same, it cannot later rescind that finding after an ANDA is submitted except in two circumstances: (1) the listed drug’s formulation has changed and the prior formulation was withdrawn for safety or effectiveness reasons, or (2) FDA issues a written determination that an earlier finding was erroneous. The latter requires written notice and a copy of the error determination to the requester, giving applicants a procedural avenue to respond or rely on the earlier agency position.
Required draft and final guidance on determination methodology
The bill mandates that FDA publish draft guidance within one year describing how it will decide qualitative/quantitative sameness — explicitly including how it will treat pH adjusters — give at least 60 days for public comment, then finalize guidance within one year after the comment window closes. This creates a predictable administrative timetable for industry to understand the technical tests and thresholds FDA will apply.
Legal authorization for disclosures and immediate applicability
The statute states that required disclosures are authorized by law (citing confidentiality law), which aims to remove legal uncertainty that might otherwise prevent FDA from sharing proprietary ingredient data with applicants. The bill also makes the new disclosure duty effective on enactment, so applicants can request determinations even before the guidance is finalized.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Generic drug developers and ANDA filers — gain clear, actionable information about inactive-ingredient matches and quantitative deviations that can reduce trial-and-error reformulation and shorten time-to-filing.
- Contract manufacturers and formulation scientists — receive precise agency feedback on excipient specifications and pH-adjuster treatment, enabling targeted adjustments rather than broad redevelopment.
- Healthcare purchasers and payers — stand to benefit indirectly if faster or more predictable generic approvals increase competition and lower prices.
- FDA reviewers (procedurally) — benefit from a standardized expectation that determinations be translated into explicit ingredient-level findings, which can improve review consistency and reduce back-and-forth.
Who Bears the Cost
- FDA — must allocate staff time and scientific resources to produce written ingredient-specific determinations, issue and manage rulemaking-style guidance with public comment, and defend rescission decisions, all without dedicated funding in the bill.
- Brand-name drug sponsors — face increased disclosure of formulation distinctions that could undermine strategic ambiguity about excipient choices and may prompt more challenges to exclusivity or patent-based defenses.
- Applicants who rely on proprietary or complex excipient strategies — may need additional laboratory testing, stability studies, or reformulation costs if FDA identifies precise quantitative deviations.
- Legal and compliance teams — will incur costs analyzing written error determinations, responding to notices, and litigating disputes over whether FDA appropriately quantified deviations or improperly rescinded a finding.
Key Issues
The Core Tension
The bill pits the industry’s need for certainty and speed in bringing generics to market against the government’s duty to protect proprietary formulation data and to apply rigorous, often resource-intensive scientific review; increasing transparency reduces applicant uncertainty but raises confidentiality, workload, and scientific-standarding dilemmas with no easy fix.
The bill translates what has often been an implicit, technical FDA judgment into a binary, documented determination with numeric detail. That clarity helps applicants but creates several practical headaches.
First, naming and quantifying deviations could compel FDA to handle more granular chemistry data, increasing reviewer workload and the need for consistent analytical standards. Second, disclosing ingredient-level differences risks exposing trade-secret formulation details; the statute attempts to blunt that by citing legal authorization for disclosures, but it does not specify how FDA will protect confidential business information in practice.
Third, the immediate effective date means parties can request determinations before the agency’s mandated guidance is final, raising the risk of inconsistent early determinations and subsequent disputes over methodology.
Operationally, the requirement to quantify deviations raises technical questions the bill leaves open: What analytical methods and acceptance criteria will FDA use across dosage forms? How will FDA treat complex excipients or proprietary blends?
The guidance timeline is helpful, but the bill ties no funding or staffing to the new obligations, so implementation quality will depend on agency resources and prioritization. Finally, limiting rescission rights narrows FDA’s flexibility to respond to new safety science; while the carve-out for withdrawals due to safety and for identified errors exists, it may not capture borderline cases where a subsequent safety signal emerges that was not obvious at the time of the initial determination.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.